Studies have demonstrated a beneficial effect of anti-TNF therapy in kidney disease. However, experience with the use of anti-TNF therapy in the clinic over the past 25 years has demonstrated that only 50% of patients respond to therapy.
We have demonstrated that the cold shock protein Y-box binding protein-1 (YB-1) is an abundant serum protein and that it possesses the ability to compete with TNF for TNFR binding. This project aims to investigate whether YB-1 is responsible for setting the threshold of TNFR signaling.
Kooperationen im Projekt
Leipziger Str. 44
Tel.:+49 391 6724703